Evidence map›Paper›PMID 32485849›Full record

ArticleCancers2020

Tailored Functionalized Magnetic Nanoparticles to Target Breast Cancer Cells Including Cancer Stem-Like Cells.

Ana Lazaro-Carrillo, Macarena Calero, Antonio Aires, Aitziber L Cortajarena, Bruno M Simões, Alfonso Latorre, Álvaro Somoza, Robert B Clarke, Rodolfo Miranda, Angeles Villanueva

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Adrenocortical Cancer Cell uptake of Iron Oxide Nanoparticles.bioRxiv : the preprint server for biology · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. The therapeutic effect of PEI-FeFrontiers in oncology · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ana Lazaro-CarrilloDepartamento de Biología, Universidad Autónoma de Madrid, Darwin 2, 28049 Madrid, Spain.ORCID 0000-0002-7733-6114
Macarena CaleroDepartamento de Biología, Universidad Autónoma de Madrid, Darwin 2, 28049 Madrid, Spain.
Antonio AiresInstituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia), Faraday 9, 28049 Madrid, Spain.ORCID 0000-0002-9339-519X
Aitziber L CortajarenaInstituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia), Faraday 9, 28049 Madrid, Spain.ORCID 0000-0002-5331-114X
Bruno M SimõesBreast Cancer Now Research Unit, Division of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, 555 Wilmslow Road, Manchester M20 4GJ, UK.ORCID 0000-0003-1253-6657
Alfonso LatorreInstituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia), Faraday 9, 28049 Madrid, Spain.
Álvaro SomozaInstituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia), Faraday 9, 28049 Madrid, Spain.
Robert B ClarkeBreast Cancer Now Research Unit, Division of Cancer Sciences, University of Manchester, Manchester Cancer Research Centre, 555 Wilmslow Road, Manchester M20 4GJ, UK.ORCID 0000-0001-5407-3123
Rodolfo MirandaInstituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia), Faraday 9, 28049 Madrid, Spain.
Angeles VillanuevaDepartamento de Biología, Universidad Autónoma de Madrid, Darwin 2, 28049 Madrid, Spain.
Madrid Institute for Advanced Studies · ESBreast Cancer Now · GBUniversidad Autónoma de Madrid · ES

Funding

FACILITY FOR MED UNIV OF SC CTR FOR SUBST ABUSE RESEARCHC06DA007809 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALLENGER, JAMES C · 1991 to 1991
–
Breast Cancer Now MAN-Q2Comunidad de Madrid IND2017/IND-7809Comunidad de Madrid S2017/BMD-3867 RENIM-CMComunidad de Madrid S2018/NMT-4321 NANOMAGCOST-CMEkonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza KK- 2017/00008Fundación Científica Asociación Española Contra el Cáncer Singulares 2014Horizon 2020 685795Manchester Biomedical Research Centre IS-BRC-1215-20007Ministerio de Ciencia e Innovación SAF2017-87305-RMinisterio de Economía, Industria y Competitividad, Gobierno de España BIO2016-77367-C2-1-RMinisterio de Economía, Industria y Competitividad, Gobierno de España CTQ2016-78454-C2-2-RSeventh Framework Programme 262943
6 · The paper itself

Abstract

Nanotechnology-based approaches hold substantial potential to avoid chemoresistance and minimize side effects. In this work, we have used biocompatible iron oxide magnetic nanoparticles (MNPs) called MF66 and functionalized with the antineoplastic drug doxorubicin (DOX) against MDA-MB-231 cells. Electrostatically functionalized MNPs showed effective uptake and DOX linked to MNPs was more efficiently retained inside the cells than free DOX, leading to cell inactivation by mitotic catastrophe, senescence and apoptosis. Both effects, uptake and cytotoxicity, were demonstrated by different assays and videomicroscopy techniques. Likewise, covalently functionalized MNPs using three different linkers-disulfide (DOX-S-S-Pyr, called MF66-S-S-DOX), imine (DOX-I-Mal, called MF66-I-DOX) or both (DOX-I-S-S-Pyr, called MF66-S-S-I-DOX)-were also analysed. The highest cell death was detected using a linker sensitive to both pH and reducing environment (DOX-I-S-S-Pyr). The greatest success of this study was to detect also their activity against breast cancer stem-like cells (CSC) from MDA-MB-231 and primary breast cancer cells derived from a patient with a similar genetic profile (triple-negative breast cancer). In summary, these nanoformulations are promising tools as therapeutic agent vehicles, due to their ability to produce efficient internalization, drug delivery, and cancer cell inactivation, even in cancer stem-like cells (CSCs) from patients.

Indexed as

apoptosiscancer stem-like cellsdoxorubicinmagnetic iron oxide nanoparticlesmitotic catastrophesenescence

Identifiers

PMID32485849
PMCPMC7352336
OpenAlexW3031319985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.